Indaptus Therapeutics, Inc. (INDP)

Pharmaceutical Preparations · market cap $489M · as of 2026-07-07

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-11 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Indaptus Therapeutics (INDP) is a clinical-stage pharmaceutical company with 7 employees and a market cap of ~$343M, developing Decoy20, a Phase 2 asset targeting solid tumors in adults. The company has critically insufficient cash — $1.5M on hand with an estimated 0.6-month runway — making near-term dilutive financing an existential certainty rather than a tail risk.

The catalyst path

2026-11-11 (est.)Earningsimp 5/10
2027-06-30 (est.)Phase 2 · Decoy20imp 7/10

Pipeline

Asset	Phase	Indication
Decoy20	Phase 2	Solid Tumor, Adult

Price & technical context

3-month

-18.6%

6-month

+45.0%

12-month

-33.7%

52-wk range

$0.94–$4.75

vs 50-day MA

+18.0%

vs 200-day MA

+2.3%

Realized vol

181.4%

Max drawdown

-98.2%

Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for INDP (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.